MCID: SCH011
MIFTS: 33

Schizotypal Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Schizotypal Personality Disorder

About this section

Aliases & Descriptions for Schizotypal Personality Disorder:

Name: Schizotypal Personality Disorder 11 50 39 13 68
 
Schizotypal Personality 50

Classifications:



External Ids:

Disease Ontology11 DOID:10646
ICD1030 F21
ICD9CM32 301.22
SNOMED-CT62 231486008, 31027006
MeSH39 D012569
NCIt45 C92632

Summaries for Schizotypal Personality Disorder

About this section
Disease Ontology:11 A personality disorder that involves a need for social isolation, anxiety in social situations, odd behavior and thinking, and often unconventional beliefs.

MalaCards based summary: Schizotypal Personality Disorder, also known as schizotypal personality, is related to schizophrenia and avoidant personality disorder. An important gene associated with Schizotypal Personality Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways are Androgen receptor signaling pathway and Metabolism. Affiliated tissues include testes, brain and eye, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and nervous system.

Wikipedia:71 Schizotypal personality disorder (STPD) or schizotypal disorder is a mental disorder characterized by... more...

Related Diseases for Schizotypal Personality Disorder

About this section

Graphical network of diseases related to Schizotypal Personality Disorder:



Diseases related to schizotypal personality disorder

Symptoms & Phenotypes for Schizotypal Personality Disorder

About this section

GenomeRNAi Phenotypes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-359.8EP300, SULT4A1

MGI Mouse Phenotypes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036317.7CACNA1C, COMT, EP300, FLNA, PSAT1

Drugs & Therapeutics for Schizotypal Personality Disorder

About this section

Drugs for Schizotypal Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Guanfacineapproved, investigationalPhase 4, Phase 25629110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
2Neurotransmitter AgentsPhase 4, Phase 2, Phase 117734
3Adrenergic AgentsPhase 4, Phase 25140
4Antihypertensive AgentsPhase 4, Phase 24095
5Adrenergic alpha-AgonistsPhase 4, Phase 21625
6Adrenergic AgonistsPhase 4, Phase 22877
7Adrenergic alpha-2 Receptor AgonistsPhase 4, Phase 2911
8
DopamineapprovedPhase 2, Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
9
Risperidoneapproved, investigationalPhase 1, Phase 2487106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
10DihydrexidinePhase 24
11Dopamine AgentsPhase 2, Phase 13759
12Dopamine agonistsPhase 2618
13
SerotoninPhase 1, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
14Serotonin AntagonistsPhase 1, Phase 21381
15Serotonin AgentsPhase 1, Phase 23102
16Tranquilizing AgentsPhase 1, Phase 24164
17Psychotropic DrugsPhase 1, Phase 26279
18Central Nervous System DepressantsPhase 1, Phase 212806
19Antipsychotic AgentsPhase 1, Phase 22359
20Dopamine AntagonistsPhase 1, Phase 21083
21Protective AgentsPhase 27190
22Peripheral Nervous System AgentsPhase 222776
23Autonomic AgentsPhase 29774
24
Oxytocinapproved, vet_approvedPhase 140850-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
25OxytocicsPhase 1660
26
Sertralineapproved29579617-96-268617
Synonyms:
(+)-Sertraline
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
(1S,4S)-Sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
79559-97-0 (Hydrochloride)
79617-96-2
AB00514002
AB1004870
AC-15639
AC1L2A41
AC1Q3O5N
AC1Q3XJU
Apo-Sertraline
BIDD:GT0768
BIDD:PXR0193
BPBio1_001285
BRD-K82036761-003-02-1
BRN 5753709
BSPBio_001167
BSPBio_002698
C07246
C17H17Cl2N
CHEBI:9123
CHEMBL809
CID68617
CP 51974
Cp 51974
D02360
DB01104
DB08567
FT-0081122
HSDB 7037
KBio3_001918
 
KBioGR_001724
LS-94179
Lustral
MLS001195647
MLS002222308
MolPort-002-885-860
NCGC00092386-03
NCGC00092386-04
NCGC00092386-05
NCGC00092386-06
NCGC00092386-07
NCGC00092386-08
NCGC00092386-09
Prestwick3_001014
SMR000596516
SPBio_000385
SRE
Sertralina
Sertralina [Spanish]
Sertraline
Sertraline (INN)
Sertraline Hydrochloride
Sertraline [INN:BAN]
Sertraline [Zoloft]
Sertraline hydrochloride
Sertralinum
Sertralinum [Latin]
Spectrum2_000493
Spectrum3_001079
Spectrum4_001232
Sultamicillin Tosylate
UNII-QUC7NX6WMB
Zoloft
cis-(+)-Sertraline
sertraline
sertraline (Zoloft)
27
Aripiprazoleapproved, investigational353129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
28Serotonin Uptake Inhibitors1570
29Antidepressive Agents2666
30Neurotransmitter Uptake Inhibitors3464
31
Silicon947440-21-34082203
Synonyms:
Si
 
Silica
Silicate
Silicic acid

Interventional clinical trials:

(show all 19)
idNameStatusNCT IDPhase
1Pharmacology of Cognition in Schizotypal Personality DisorderUnknown statusNCT00353379Phase 4
2Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality DisorderUnknown statusNCT01466205Phase 2
3Schizotypal Personality Disorder RisperidoneCompletedNCT02535156Phase 1, Phase 2
4A D1 Agonist For Working MemoryRecruitingNCT02507206Phase 2
5CRT-Guanfacine for SPDRecruitingNCT02524899Phase 2
6Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsRecruitingNCT02149823Phase 1
7Pergolide for Cognitive Symptoms in Schizotypal Personality DisorderUnknown statusNCT00252044
8Health Promotion on Young Adults With High Risk Disability for Mental HealthUnknown statusNCT01740167
9Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality DisorderCompletedNCT00158028
10A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological DysfunctionsCompletedNCT00155519
11Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative SymptomsCompletedNCT00169988
12Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of PsychosisCompletedNCT01619319
13Extended Specialized Assertive Intervention for First Episode PsychosisCompletedNCT00914238
14Psychosis: Early Detection, Intervention and PreventionCompletedNCT01597141
15Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) StudyCompletedNCT01269710
16Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult SampleRecruitingNCT02800681
17Personality Pathology and Cerebral Processing in Eating DisordersRecruitingNCT02980120
18Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode PsychosisActive, not recruitingNCT00157313
19Aripiprazole Treatment of the ProdromeTerminatedNCT00169949

Search NIH Clinical Center for Schizotypal Personality Disorder


Cochrane evidence based reviews: schizotypal personality disorder

Genetic Tests for Schizotypal Personality Disorder

About this section

Anatomical Context for Schizotypal Personality Disorder

About this section

MalaCards organs/tissues related to Schizotypal Personality Disorder:

36
Testes, Brain, Eye, Caudate nucleus, Temporal lobe, Pituitary, Cortex

Publications for Schizotypal Personality Disorder

About this section

Articles related to Schizotypal Personality Disorder:

(show top 50)    (show all 185)
idTitleAuthorsYear
1
Decreased fractional anisotropy values in two clusters of white matter in patients with schizotypal personality disorder: A DTI study. (27178397)
2016
2
Biological Motion Perception, Brain Responses, and Schizotypal Personality Disorder. (26790398)
2016
3
Characterization of the Fiber Connectivity Profile of the Cerebral Cortex in Schizotypal Personality Disorder: A Pilot Study. (27303358)
2016
4
Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. (27330977)
2016
5
Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia. (25482574)
2015
6
Screening schizotypal personality disorder for detection of clinical high risk of psychosis in Chinese mental health services. (26165958)
2015
7
The melbourne assessment of Schizotypy in kids: a useful measure of childhood schizotypal personality disorder. (25629050)
2015
8
Schizotypal personality disorder: a current review. (24828284)
2014
9
White Matter Abnormalities in Schizophrenia and Schizotypal Personality Disorder. (24962608)
2014
10
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. (25074637)
2014
11
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [(11)C]NNC112. (24781514)
2014
12
DSM-IV schizotypal personality disorder: a taxometric analysis among individuals with and without substance use disorders in the general population. (26322122)
2014
13
Altered default mode network functional connectivity in schizotypal personality disorder. (25458858)
2014
14
Visual-spatial working memory performance and temporal gray matter volume predict schizotypal personality disorder group membership. (24398009)
2014
15
Openness to experience, intellect, schizotypal personality disorder, and psychoticism: resolving the controversy. (24511900)
2014
16
Schizotypal personality disorder. (22928856)
2013
17
Neuroimaging findings in schizotypal personality disorder: a systematic review. (23220094)
2013
18
Semantic processing impairment in individuals with schizotypal personality disorder features: a preliminary event-related potential study. (22960083)
2013
19
CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. (22985546)
2013
20
Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. (24200416)
2013
21
Prodromal and autistic symptoms in schizotypal personality disorder and 22q11.2 deletion syndrome. (22686870)
2013
22
Does a latent class underlie schizotypal personality disorder? Implications for schizophrenia. (23713503)
2013
23
Globally and locally reduced MRI gray matter volumes in neuroleptic-naive men with schizotypal personality disorder: association with negative symptoms. (23389420)
2013
24
Working memory in schizotypal personality disorder: fMRI activation and deactivation differences. (24161536)
2013
25
Empathic accuracy and cognition in schizotypal personality disorder. (23810511)
2013
26
Developmental trajectories of schizotypal personality disorder-like behavioural manifestations: a two-year longitudinal prospective study of college students. (24289659)
2013
27
Larger putamen size in antipsychotic-naA^ve individuals with schizotypal personality disorder. (23187070)
2013
28
Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. (23375943)
2013
29
Some suggestions for the DSM-5 schizotypal personality disorder construct. (21741634)
2012
30
A review of structural MRI and diffusion tensor imaging in schizotypal personality disorder. (22006127)
2012
31
Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. (22325079)
2012
32
Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder. (22285558)
2012
33
Anterior limb of the internal capsule in schizotypal personality disorder: fiber-tract counting, volume, and anisotropy. (22995934)
2012
34
Prosodic abnormalities in schizotypal personality disorder. (23068317)
2012
35
Dorso- and ventro-lateral prefrontal volume and spatial working memory in schizotypal personality disorder. (21115066)
2011
36
Deficient visual sensitivity in schizotypal personality disorder. (20541911)
2011
37
Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder. (21507614)
2011
38
Facial emotion recognition and facial affect display in schizotypal personality disorder. (21640557)
2011
39
A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression. (20955740)
2011
40
The differential effects of child abuse and posttraumatic stress disorder on schizotypal personality disorder. (21683181)
2011
41
Cingulate and temporal lobe fractional anisotropy in schizotypal personality disorder. (21223999)
2011
42
Evidence of reduced selective attention in schizotypal personality disorder. (21526445)
2011
43
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. (20130535)
2010
44
Increased temporal variability of auditory event-related potentials in schizophrenia and Schizotypal Personality Disorder. (20817485)
2010
45
Childhood adversity, mental disorder comorbidity, and suicidal behavior in schizotypal personality disorder. (21048469)
2010
46
Factors in sensory processing of prosody in schizotypal personality disorder: an fMRI experiment. (20362418)
2010
47
Smaller superior temporal gyrus volume specificity in schizotypal personality disorder. (19473820)
2009
48
Dichotic listening in schizotypal personality disorder: evidence for gender and laterality effects. (19464150)
2009
49
Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions. (19617934)
2009
50
Shape abnormalities of caudate nucleus in schizotypal personality disorder. (19328654)
2009

Variations for Schizotypal Personality Disorder

About this section

Expression for genes affiliated with Schizotypal Personality Disorder

About this section
Search GEO for disease gene expression data for Schizotypal Personality Disorder.

Pathways for genes affiliated with Schizotypal Personality Disorder

About this section

Pathways related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.1EP300, FLNA
2
Show member pathways
7.6CACNA1C, COMT, EP300, PSAT1, SULT4A1

GO Terms for genes affiliated with Schizotypal Personality Disorder

About this section

Biological processes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein stabilizationGO:00508219.1EP300, FLNA

Molecular functions related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1SMAD bindingGO:00463329.1EP300, FLNA

Sources for Schizotypal Personality Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet